U.S. Government & Politics
What are the economic and legal implications of President Trump’s DEI and LGBTQIA executive orders?
In the race to end the COVID-19 pandemic, the world saw an unprecedented process to quickly research, develop, test, and deploy a vaccine to protect against the virus. But like many other facets of life, the pandemic also exposed, and in some cases exacerbated, problems in drug and medical supply manufacturing. Global supply chains were disrupted leading to shortages of medicines and personal protective equipment. Many health care systems around the country were overwhelmed with sick patients, calling into question the ability to provide quality health care to Americans.
On June 11, Governance Studies at Brookings and the Olin Business School at Washington University in St. Louis cohosted a webinar to discuss pharmaceutical drug manufacturing and supply chain logistics in the aftermath of the COVID-19 pandemic. Panelists unpacked current obstacles in manufacturing drugs and medical supplies in the United States and solutions to those barriers.
Viewers submitted questions for speakers by emailing [email protected] or via Twitter at @BrookingsGov by using #USSupplyChain.
Agenda
-
June 11
-
Panel
Moderator
Darrell M. West Senior Fellow - Governance Studies, Center for Technology Innovation (CTI), Center for Effective Public Management (CEPM), Douglas Dillon Chair in Governmental Studies @Panelist
Spiro Gavaris President, Specialty Generics - Mallinckrodt
Edward Price Consultant, Former President and CEO - PCI Synthesis
Tony Sardella Adjunct Professor and Senior Research Advisor, Olin School of Business and Center for Analytics and Business Insights - Washington University in St. Louis
David H. Thompson Co-Founder & Chief Technology Officer - Continuity Pharma, Professor of Chemistry - Purdue University
-
